Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ERN1 | O75460 | 1/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135204 | 0.79 | HTR1A (0.44) | HTR1AACMSD | |
| SCHEMBL30302079 | 0.79 | CHRNB4 (0.50) | HTR1AACMSD | |
| SCHEMBL5387084 | 0.79 | HTR1A (0.44) | HTR1AACMSD | |
| SCHEMBL5383499 | 0.79 | CHRNB4 (0.50) | HTR1AACMSD | |
| SCHEMBL29644212 | 0.77 | AGXT (0.55) | L3MBTL1ERN1BRD4CREBBP | |
| SCHEMBL1338691 | 0.77 | AGXT (0.55) | L3MBTL1ERN1BRD4CREBBP | |
| SCHEMBL5268060 | 0.76 | NCOA1 (0.47) | PDGFRBPDGFRA | |
| SCHEMBL5266330 | 0.75 | MAOB (0.49) | HTR1ABRD4 | |
| SCHEMBL30317738 | 0.75 | MAOB (0.49) | HTR1ABRD4 | |
| SCHEMBL15725255 | 0.75 | HTR1A (0.47) | HTR1AACMSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927105-B1 | Pyrazole MAGL inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2021-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927105-B1 | Pyrazole MAGL inhibitors | MGLL, PNLIP, LPL | HTR1A 2852/4885L3MBTL1 1901/4885ERN1 1347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.